JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (12): 94-96.doi: 10.6040/j.issn.1671-7554.0.2015.093

Previous Articles    

  

  • Received:2015-01-16 Online:2015-12-10 Published:2015-12-10

CLC Number: 

  • R658.3
[1] Korf BR. Diagnosis and management of neurofibromatosis type1[J]. Curr Neurol Neurosci Rep, 2001, 1(2):162-167.
[2] Duman O, Ozdemb S, Turkkahraman D, et al. Bone metabolism markers and bone mineral density in children with neurofibromatosis type1[J]. Brain Dev, 2008, 30(9):584-588.
[3] Vitale MG, Guha A, Skaggs DL. Orthopaedic manifestations of neurofibromatosis in children:an update[J]. Clin Orthop RelatRes, 2002, 401:107-118.
[4] Roberts L. Down to the wire for the NF gene[J]. Science, 1990, 249(4966):236-238.
[5] Patel NP, Mhatre AN, Lalwani AK. Molecularpathogenesis of skull base tumors[J]. Otol Neurotol, 2004, 25(4):636-643.
[6] Yohay KH. The genetic and molecular pathogenesis of NF1 and NF2[J]. Senmin Pediator Neurol, 2006, 13(1):21-26.
[7] 齐向东,王伟民,张斌,等.数字化辅助技术在神经纤维瘤手术方案选择中的应用[J].组织工程与重建外科杂志,2014,10(1):51-53.
[8] Kim S, Roh S, Lee N, et al. Radiofrequency ablation and excision of multiple cutaneous lesions in neurofibromatosis type1[J]. Arch Facial Plast S, 2013, 40(1):57-61.
[9] Maruta H. Effective neurofibromatosis therapeutics blocking theoncogenic kinase PAK1[J]. Drug Discov Ther, 2011, 5(6):266-278.
No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!